{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:32:01Z","timestamp":1786606321853,"version":"build-2736575974"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":224,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatrics International"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Valproic acid (VPA) and levetiracetam (LEV) are among the most widely used anti\u2010seizure medications (ASMs) in pediatric epilepsy. Although they share the common goal of seizure control, these drugs exhibit distinct pharmacokinetic characteristics, which can influence therapeutic drug monitoring (TDM), dosing strategies, and treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      This study aims to compare the intra\u2010drug pharmacokinetic profiles of VPA and LEV in pediatric patients, focusing on dose\u2010normalized concentration (C\n                      <jats:sub>0<\/jats:sub>\n                      \/mg\/kg). The study also investigates the impact of concomitant enzyme\u2010inducing or enzyme\u2010inhibiting drugs on these parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The analysis included 1141 serum samples from 817 patients (447 VPA; 370 LEV). Pediatric patients receiving monotherapy or combination therapy with one of two anti\u2010seizure medications were retrospectively analyzed. Pharmacokinetic indices were compared using descriptive and nonparametric methods. Subgroup analysis was performed according to concomitant drugs affecting liver metabolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A moderately positive correlation was observed between daily LEV dose and serum concentration (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.47,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), while VPA showed a weaker but significant dose\u2010concentration relationship (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.31,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001;\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.096). Dose\u2010normalized minimum concentrations (C\n                      <jats:sub>0<\/jats:sub>\n                      \/mg\/kg) differed significantly between treatment groups for both drugs. In the VPA group, concomitant use of enzyme inducers was associated with significantly lower C\n                      <jats:sub>0<\/jats:sub>\n                      \/mg\/kg values compared with both monotherapy and neutral co\u2010medication groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Similarly, the LEV+ inducer group showed significantly different C\n                      <jats:sub>0<\/jats:sub>\n                      \/mg\/kg values than levetiracetam monotherapy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). Neutral concomitant drugs did not significantly affect C\n                      <jats:sub>0<\/jats:sub>\n                      \/mg\/kg for either drug.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Concomitant enzyme\u2010inducing ASM significantly reduced dose\u2010normalized trough concentrations of VPA and LEV, while neutral co\u2010medications had no effect, highlighting the importance of TDM in pediatric combination therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ped.70510","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:24:06Z","timestamp":1786605846000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concomitant Antiseizure Medications' Influence on Valproic Acid and Levetiracetam Pharmacokinetics in Pediatric Patients"],"prefix":"10.1111","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2281-1712","authenticated-orcid":false,"given":"Z\u00fchal","family":"Kaltu\u015f","sequence":"first","affiliation":[{"name":"Medical Pharmacology of Eskisehir City Hospital  Eskisehir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1598-4423","authenticated-orcid":false,"given":"Sevgi","family":"Yimenicio\u011flu","sequence":"additional","affiliation":[{"name":"Pediatric Neurology Department, Health Practice and Research Centers Eski\u015fehir City Hospital, Health Sciences University  Eskisehir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9878-3431","authenticated-orcid":false,"given":"Ezgi","family":"Ero\u011flu","sequence":"additional","affiliation":[{"name":"Clinical Research Department Turkish Medicines and Medical Devices Agency  Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8735-0326","authenticated-orcid":false,"given":"Cefa Nil Arslan","family":"Karademir","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurology Eski\u015fehir City Hospital  Eskisehir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"9509","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(06)68182-8","article-title":"Epilepsy in Children","volume":"367","author":"Guerrini R.","year":"2006","journal-title":"Lancet"},{"issue":"4","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised Terminology and Concepts for Organization of Seizures and Epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005\u20132009","volume":"51","author":"Berg A. T.","year":"2010","journal-title":"Epilepsia"},{"issue":"3","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1528-1157.43.s.3.3.x","article-title":"Epileptic Syndromes in Childhood: Clinical Features, Outcomes, and Treatment","volume":"43","author":"Camfield P.","year":"2002","journal-title":"Epilepsia"},{"issue":"2","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/epi.12179","article-title":"Predicting Pharmacoresistance in Pediatric Epilepsy","volume":"54","author":"Wirrell E. C.","year":"2013","journal-title":"Epilepsia"},{"issue":"5","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1474-4422(11)70047-3","article-title":"The Pharmacological Treatment of Epilepsy in Adults","volume":"10","author":"Perucca E.","year":"2011","journal-title":"Lancet Neurology"},{"issue":"7","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Anti\u2010Seizure Medications\u2014Best Practice Guidelines for Therapeutic Drug Monitoring: A Position Paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos P. N.","year":"2008","journal-title":"Epilepsia"},{"issue":"3","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE Evidence Review of Anti\u2010Seizure Medication Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes","volume":"54","author":"Glauser T.","year":"2013","journal-title":"Epilepsia"},{"issue":"4","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200645040-00002","article-title":"Clinical Pharmacokinetics of New\u2010Generation Anti\u2010Seizure Medications at the Extremes of Age","volume":"45","author":"Perucca E.","year":"2006","journal-title":"Clinical Pharmacokinetics"},{"issue":"1","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/JNN.0000000000000259","article-title":"Valproic Acid: Special Considerations and Targeted Monitoring","volume":"49","author":"Collins\u2010Yoder A.","year":"2017","journal-title":"Journal of Neuroscience Nursing"},{"issue":"11","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical Pharmacokinetics of Levetiracetam","volume":"43","author":"Patsalos P. N.","year":"2004","journal-title":"Clinical Pharmacokinetics"},{"issue":"6","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00007691-200312000-00007","article-title":"Serum Concentrations of Levetiracetam in Epileptic Patients: The Influence of Dose and Co\u2010Medication","volume":"25","author":"May T. W.","year":"2003","journal-title":"Therapeutic Drug Monitoring"},{"issue":"5","key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40272-018-0302-4","article-title":"Pharmacokinetics and Drug Interaction of Anti\u2010Seizure Medications in Children and Adolescents","volume":"20","author":"Iapadre G.","year":"2018","journal-title":"Paediatric Drugs"},{"issue":"4","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.spen.2010.10.002","article-title":"Developmental Pharmacokinetics","volume":"17","author":"Anderson G. D.","year":"2010","journal-title":"Seminars in Pediatric Neurology"},{"issue":"12","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental Pharmacology\u2014Drug Disposition, Action, and Therapy in Infants and Children","volume":"349","author":"Kearns G. L.","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/17425255.2020.1724956","article-title":"Therapeutic Drug Monitoring of Anti\u2010Seizure Medications: Current Status and Future Prospects","volume":"16","author":"Johannessen Landmark C.","year":"2020","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"issue":"12","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1248\/bpb.27.2000","article-title":"Influence of Coadministered Anti\u2010Seizure Medications on Serum Phenobarbital Concentrations in Epileptic Patients: Quantitative Analysis Based on a Suitable Transforming Factor","volume":"27","author":"Fukuoka N.","year":"2004","journal-title":"Biological & Pharmaceutical Bulletin"},{"issue":"2","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-2004-815527","article-title":"Olanzapine Plasma Concentration, Average Daily Dose, and Interaction With Co\u2010Medication in Schizophrenic Patients","volume":"37","author":"Bergemann N.","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0920-1211(02)00250-4","article-title":"Effects of Antiepileptic Comedication on Levetiracetam Pharmacokinetics: A Pooled Analysis of Data From Randomized Adjunctive Therapy Trials","volume":"53","author":"Perucca E.","year":"2003","journal-title":"Epilepsy Research"},{"issue":"3","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neurol.2017.02.004","article-title":"Influence of Age and Co\u2010Medication on the Steady\u2010State Pharmacokinetics of Valproic Acid in Tunisian Patients With Epilepsy","volume":"173","author":"Ben Mahmoud L.","year":"2017","journal-title":"Revue Neurologique"},{"issue":"1","key":"e_1_2_12_21_1","first-page":"9","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke C.","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically Important Drug Interactions in Epilepsy: Interactions Between Anti\u2010Seizure Medications and Other Drugs","volume":"2","author":"Patsalos P. N.","year":"2003","journal-title":"Lancet Neurology"},{"issue":"4","key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/clpt.1980.192","article-title":"Valproic Acid Dosage and Plasma Protein Binding and Clearance","volume":"28","author":"Bowdle A. T.","year":"1980","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"e_1_2_12_24_1","first-page":"537","article-title":"Influence of Age and Co\u2010Medication on the Concentration and Efficacy of Valproic Acid in Chinese Epilepsy Children","volume":"33","author":"Wang Y.","year":"2020","journal-title":"Pakistan Journal of Pharmaceutical Sciences"},{"issue":"4","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00007691-200408000-00006","article-title":"Levetiracetam Therapeutic Monitoring in Patients With Epilepsy: Effect of Concomitant Anti\u2010Seizure Medications","volume":"26","author":"Contin M.","year":"2004","journal-title":"Therapeutic Drug Monitoring"},{"issue":"7","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1528-1167.2007.01043.x","article-title":"Effect of Age and Comedication on Levetiracetam Pharmacokinetics and Tolerability","volume":"48","author":"Hirsch L. J.","year":"2007","journal-title":"Epilepsia"},{"issue":"4","key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pediatrneurol.2010.05.008","article-title":"Age and Comedications Influence Levetiracetam Pharmacokinetics in Children","volume":"43","author":"Dahlin M. G.","year":"2010","journal-title":"Pediatric Neurology"},{"issue":"3","key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00309-6","article-title":"Carbamazepine Toxicity During Combination Therapy With Levetiracetam: A Pharmacodynamic Interaction","volume":"48","author":"Sisodiya S. M.","year":"2002","journal-title":"Epilepsy Research"},{"issue":"1","key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/FTD.0000000000000470","article-title":"Influence of Comedication on Levetiracetam Pharmacokinetics","volume":"40","author":"Aldaz A.","year":"2018","journal-title":"Therapeutic Drug Monitoring"},{"issue":"1","key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.eplepsyres.2011.01.007","article-title":"Influence of Enzyme Inducing Anti\u2010Seizure Medications on the Pharmacokinetics of Levetiracetam in Patients With Epilepsy","volume":"94","author":"Freitas\u2010Lima P.","year":"2011","journal-title":"Epilepsy Research"},{"issue":"1","key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-1211(02)00251-6","article-title":"Valproate Unbound Fraction and Distribution Volume Following Rapid Infusions in Patients With Epilepsy","volume":"53","author":"Cloyd J. C.","year":"2003","journal-title":"Epilepsy Research"}],"container-title":["Pediatrics International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ped.70510","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ped.70510","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ped.70510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:24:10Z","timestamp":1786605850000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ped.70510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/ped.70510"],"URL":"https:\/\/doi.org\/10.1111\/ped.70510","archive":["Portico"],"relation":{},"ISSN":["1328-8067","1442-200X"],"issn-type":[{"value":"1328-8067","type":"print"},{"value":"1442-200X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2026-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70510"}}